Clin Mol Hepatol.  2013 Mar;19(1):51-59. 10.3350/cmh.2013.19.1.51.

A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience

• Oh MJ
• Lee HJ

• KMID: 1493575
• DOI: http://doi.org/10.3350/cmh.2013.19.1.51

Abstract

BACKGROUND/AIMS
The widespread use of cytotoxic chemotherapy and immunosuppressants has resulted in reactivation of hepatitis B virus (HBV) recently becoming an issue. Although rituximab (an anti-CD20 monoclonal antibody) has revolutionized the treatment of lymphoma, recent reports have suggested that rituximab therapy increases the risk of viral-mediated complications, and particularly HBV reactivation. This study analyzed real clinical practice data for rituximab-related HBV reactivation.
METHODS
Between January 2005 and December 2011, 169 patients received treatment with rituximab. Screening status of the HBV infection and frequency of preemptive therapy were determined in these patients, and the clinical features of HBV reactivation were analyzed.
RESULTS
Seventy-nine of the 169 patients with chronic or past HBV infection were selected for evaluation of HBV reactivation. Of the 90 patients who were excluded, 22 (13.0%) were not assessed for HBsAg and anti-HBc, and 14 (8.3%) were not assessed for anti-HBc due to seronegativity for HBsAg. The selected patients were divided into those with chronic HBV infection (n=12) and those with past HBV infection (n=67); six patients (7.6%) experienced HBV reactivation. Eight patients received preemptive therapy, but three patients (37.5%) underwent HBV reactivation. Although HBsAg seropositivity was an independent risk factor for HBV reactivation (P=0.038), of the six patients with HBV reactivation, two (33.3%) had past HBV infection and three (50%) died of liver failure.
CONCLUSIONS
The findings of this study demonstrate that adherence to guidelines for screening and preemptive therapy for HBV reactivation was negligent among the included cohort. Attention should be paid to HBV reactivation in patients with past as well as chronic HBV infection during and after rituximab therapy.

Keyword

Hepatitis B virus; Immunosuppressant; Rituximab

MeSH Terms

Adolescent
Adult
Aged
Aged, 80 and over
Antibodies/blood
Antibodies, Monoclonal, Murine-Derived/*adverse effects/therapeutic use
Antineoplastic Agents/adverse effects/*therapeutic use
Child
Child, Preschool
Hepatitis B/etiology/mortality/virology
Hepatitis B Core Antigens/immunology
Hepatitis B Surface Antigens/blood
Hepatitis B virus/*physiology
Humans
Lymphoma/*drug therapy
Middle Aged
Odds Ratio
Retrospective Studies
Risk Factors
*Virus Activation
Young Adult
Antibodies
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Hepatitis B Core Antigens
Hepatitis B Surface Antigens